Acacia Research Corp (ACTG) 9.83 $ACTG Notable earnings

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:58 PM

Acacia Research Corp (ACTG) 9.83 $ACTG

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - 2 hrs 22 mins ago

MXIM: 35.00 (-0.19), AWAY: 32.27 (+0.76), GHL: 42.42 (-0.33), HBHC: 30.03 (+0.25), HWAY: 18.99 (-0.08), DV: 36.49 (+0.22), RGA: 93.16 (+0.14), FET: 21.65 (+0.74), GOOG: 539.36 (+5.39), COF: 81.76 (+0.23), FII: 34.50 (+0.44), MSFT: 42.99 (+0.36), BLDR: 13.00 (-0.09), EFII: 42.55 (+0.56), BCR: 175.09 (+0.24), LSTR: 65.26 (+0.57), ETH: 25.96 (+0.16), QDEL: 23.80 (+0.64), RSG: 39.75 (+0.16), HUBG: 37.84 (+0.04), BGS: 29.77 (-0.18), DGII: 9.40 (+0.11), PFG: 51.73 (+0.73), CPHD: 53.14 (-0.78), NTGR: 33.15 (+0.57), FSL: 41.53 (+0.49), ALTR: 42.78 (-0.46), CB: 99.30 (-0.44), N: 95.42 (+1.53), MTSN: 3.73 (+0.07), JNPR: 24.39 (+0.22), MXWL: 6.94 (-0.13), FR: 20.19 (-0.10), GIMO: 23.51 (+0.29), ELY: 9.83 (-0.23), P: 17.51 (+0.28), S: 5.08 (+0.10), RMD: 73.28 (+0.17), BJRI: 50.54 (-1.00), PEB: 45.45 (-0.08), FICO: 92.00 (-0.15), ETFC: 28.60 (+1.07), HBI: 34.12 (+0.23), CBI: 49.62 (-1.62), AMZN: 389.80 (-1.38), ALGN: 55.94 (-0.21), ACTG: 9.83 (-0.08), HA: 22.02 (-0.20), KN: 21.27 (-0.24), NEM: 22.77 (-0.74), MSCC: 35.98 (-0.16), CYN: 93.19 (+0.06), CVTI: 34.35 (-0.01), RHI: 59.59 (+0.30), QLIK: 33.68 (+0.31), MKTO: 28.84 (+0.98), BAS: 7.88 (+0.07), KLAC: 60.30 (+0.96), MMSI: 18.79 (+0.45)

First Week of ACTG June 19th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:20AM CDT
Investors in Acacia Research Corp saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACTG options chain for the new June 19th contracts and identified...
ACTG: 9.83 (-0.08)

Shares of ACTG Down 38.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 20, 11:26AM CDT
SmarTrend identified a Downtrend for Acacia Research (NASDAQ:ACTG) on January 5th, 2015 at $16.74. In approximately 4 months, Acacia Research has returned 38.91% as of today's recent price of $10.23.
ACTG: 9.83 (-0.08)

Notable tech gainers/decliners: YY, SOHU, ANGI, ACTG, IGT, VSLR, CSLT
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 2:19PM CDT

SEDG: 23.81 (+0.13), YY: 61.86 (+1.12), ACTG: 9.83 (-0.08), CEVA: 22.15 (-0.25), ANGI: 6.46 (+0.31), SOHU: 65.30 (+1.68), CSLT: 7.85 (+0.36), IDSY: 7.02 (+0.13), VSLR: 14.33 (+0.36), IGT: 19.88 (-0.02), SIMO: 33.64 (+0.15)

Acacia Research to Release First Quarter Financial Results and Host Conference Call
Business Wire - Thu Apr 16, 5:00AM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today it will release its first quarter financial results on Thursday, April 23, 2015. Results will be released at 4:00 PM (EDT) / 1:00 PM (PDT).
ACTG: 9.83 (-0.08)

Downtrend Call Working As Acacia Research Stock Falls 35.0% (ACTG)
Comtex SmarTrend(R) - Mon Apr 13, 11:26AM CDT
SmarTrend identified a Downtrend for Acacia Research (NASDAQ:ACTG) on January 5th, 2015 at $16.75. In approximately 3 months, Acacia Research has returned 34.97% as of today's recent price of $10.89.
ACTG: 9.83 (-0.08)

Acacia's subsidiary signs settlement and patent license agreement with NEC Corporation and NEC Display Solutions Ltd
M2 - Thu Apr 09, 6:04AM CDT
Patent licensing company Acacia Research Corporation (Nasdaq:ACTG) announced on Wednesday that its subsidiary Nexus Display Technologies LLC has entered into a settlement and patent license agreement with NEC Corporation and NEC Display Solutions Ltd.
ACTG: 9.83 (-0.08)

Acacia Subsidiary Enters into Settlement and Patent License Agreement with NEC Corporation and NEC Display Solutions Ltd.
Business Wire - Thu Apr 09, 5:00AM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Nexus Display Technologies LLC subsidiary has entered into a settlement and patent license agreement with NEC Corporation and NEC Display Solutions Ltd. The agreement resolves litigation that was pending in the United States District Court for the Eastern District of Texas.
ACTG: 9.83 (-0.08)

36.4% Return Seen to Date on SmarTrend Acacia Research Call (ACTG)
Comtex SmarTrend(R) - Mon Apr 06, 9:52AM CDT
SmarTrend identified a Downtrend for Acacia Research (NASDAQ:ACTG) on January 5th, 2015 at $16.75. In approximately 3 months, Acacia Research has returned 36.40% as of today's recent price of $10.65.
ACTG: 9.83 (-0.08)

Acacia Subsidiary Enters into Settlement and Patent License Agreement with DePuy Synthes, Inc. and DePuy Orthopaedics, Inc.
Business Wire - Tue Mar 31, 1:56PM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Bonutti Skeletal Innovations LLC subsidiary has entered into a settlement and patent license agreement with DePuy Synthes, Inc. and DePuy Orthopaedics, Inc. The agreement resolves litigation that was pending in the United States District Court for the District of Massachusetts.
ACTG: 9.83 (-0.08)

Acacia Subsidiaries Enter into Patent License Agreements with Sony Mobile Communications Inc.
Business Wire - Tue Mar 31, 12:28PM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Saint Lawrence Communications LLC and Saint Lawrence Communications GmbH subsidiaries have entered into patent license agreements with Sony Mobile Communications Inc.
ACTG: 9.83 (-0.08)

Acacia's subsidiary and Elavon enter into settlement and patent license agreement
M2 - Tue Mar 31, 3:00AM CDT
Patent licensing company Acacia Research Corporation (Nasdaq:ACTG) announced on Monday that its subsidiary, Credit Card Fraud Control Corporation, has entered into a settlement and patent license agreement with Elavon Inc.
ACTG: 9.83 (-0.08)

Acacia Subsidiary Enters into Settlement and Patent License Agreement with Elavon, Inc.
Business Wire - Mon Mar 30, 5:00AM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Credit Card Fraud Control Corporation subsidiary has entered into a settlement and patent license agreement with Elavon, Inc. The agreement resolves litigation that was pending in the United States District Court for the Northern District of Texas.
ACTG: 9.83 (-0.08)

Acacia's subsidiary announces settlement and patent license agreement with Leica Microsystems GmbH and Leica Microsystems
M2 - Fri Mar 27, 4:32AM CDT
Patent licensing company Acacia Research Corporation (Nasdaq:ACTG) announced on Thursday that its subsidiary, Super Resolution Technologies LLC, has entered into a settlement and patent license agreement with Leica Microsystems GmbH and Leica Microsystems Inc.
ACTG: 9.83 (-0.08)

Acacia Subsidiary Enters into Settlement and Patent License Agreement with Leica Microsystems GmbH and Leica Microsystems Inc.
Business Wire - Thu Mar 26, 5:00AM CDT
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Super Resolution Technologies LLC subsidiary has entered into a settlement and patent license agreement with Leica Microsystems GmbH and Leica Microsystems Inc. The agreement resolves litigation that was pending in the United States District Court for the Southern District of Texas.
ACTG: 9.83 (-0.08)

New Patent Legislation: Impacts On Publicly-Traded Patent Investments
IP Hawk - at Seeking Alpha - Wed Mar 25, 4:46PM CDT

WILN: 2.47 (unch), ACTG: 9.83 (-0.08), PRKR: 0.72 (-0.03), MARA: 5.78 (+0.08), ACOR: 33.34 (-1.33), VHC: 6.85 (+0.22)

Methode Electronics, Acacia Research, Kroger, SUPERVALU and Whole Foods Market highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 8:30AM CDT
Methode Electronics, Acacia Research, Kroger, SUPERVALU and Whole Foods Market highlighted as Zacks Bull and Bear of the Day
WFM: 48.60 (-0.37), KR: 70.39 (-1.44), ACTG: 9.83 (-0.08), SVU: 11.01 (-0.10), MEI: 44.65 (+0.74)

Bear of the Day: Acacia Research (ACTG) - Bear of the Day
Kevin Cook - Zacks Investment Research - Tue Mar 24, 8:01AM CDT
Bear of the Day: Acacia Research (ACTG) - Bear of the Day
ACTG: 9.83 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...